AlloVir, Inc. (NASDAQ:ALVR - Get Free Report) shares hit a new 52-week low on Thursday . The stock traded as low as $7.97 and last traded at $8.40, with a volume of 12995 shares trading hands. The stock had previously closed at $8.77.
AlloVir Trading Up 3.1 %
The company has a market cap of $1.07 billion, a price-to-earnings ratio of -10.55 and a beta of 0.65. The business's 50 day moving average price is $0.67 and its 200-day moving average price is $0.74.
AlloVir (NASDAQ:ALVR - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10.
Institutional Trading of AlloVir
A hedge fund recently bought a new stake in AlloVir stock. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of AlloVir, Inc. (NASDAQ:ALVR - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 76,278 shares of the company's stock, valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.07% of AlloVir as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 66.05% of the company's stock.
AlloVir Company Profile
(
Get Free Report)
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Featured Articles
Before you consider AlloVir, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AlloVir wasn't on the list.
While AlloVir currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
